A real-world comparison study of the efficacy of dual-target first-line rescue treatment of human epidermal growth factor receptor 2 positive advanced breast cancer: trastuzumab combined with pertuzumab versus trastuzumab combined with pyrotinib

Overall, the results of the current study suggested that HPyr could be equivalently used as HP, as a first-line treatment strategy for patients with HER2-positive ABC. Currently, more prospective large-sample studies are needed to further validate our conclusions.